MLchartDataset catalogue

EZN-2285

Term · Oncology and biomedicine · MLC-T-ONC-003105

A drug used with other drugs to treat acute lymphoblastic leukemia in children and young adults aged 1 month to 21 years. It is also being studied in the treatment of other types of cancer. EZN-2285 is made up of the enzyme L-asparaginase that is linked to a substance called SC-PEG, which makes the drug stay in the body longer. L-asparaginase comes from the bacterium E. coli and breaks down the amino acid asparagine. This may stop the growth of cancer cells that need asparagine to grow. EZN-2285 is a type of protein synthesis inhibitor. Also called Asparlas, calaspargase pegol, and SC-PEG E. coli L-asparaginase.

Table 1. Record
IdentifierMLC-T-ONC-003105
FieldOncology and biomedicine
ExpansionsAsparlas; calaspargase pegol; SC-PEG E
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-003105",
  "term": "EZN-2285",
  "field": "Oncology and biomedicine",
  "definition": "A drug used with other drugs to treat acute lymphoblastic leukemia in children and young adults aged 1 month to 21 years. It is also being studied in the treatment of other types of cancer. EZN-2285 is made up of the enzyme L-asparaginase that is linked to a substance called SC-PEG, which makes the drug stay in the body longer. L-asparaginase comes from the bacterium E. coli and breaks down the amino acid asparagine. This may stop the growth of cancer cells that need asparagine to grow. EZN-2285 is a type of protein synthesis inhibitor. Also called Asparlas, calaspargase pegol, and SC-PEG E. coli L-asparaginase.",
  "expansions": [
    "Asparlas",
    "calaspargase pegol",
    "SC-PEG E"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/ezn-2285/"
}

Record 7,098 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.